- Home
- CMMB vs BCAB Comparison
CMMB vs BCAB Comparison
Compare CMMB & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- BCAB
- Stock Information
- Founded
- CMMB 2004
- BCAB 2007
- Country
- CMMB Israel
- BCAB United States
- Employees
- CMMB N/A
- BCAB N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- CMMB Health Care
- BCAB Health Care
- Exchange
- CMMB Nasdaq
- BCAB Nasdaq
- Market Cap
- CMMB 23.6M
- BCAB 27.0M
- IPO Year
- CMMB N/A
- BCAB 2020
- Fundamental
- Price
- CMMB $1.20
- BCAB $0.38
- Analyst Decision
- CMMB Strong Buy
- BCAB Buy
- Analyst Count
- CMMB 2
- BCAB 2
- Target Price
- CMMB $9.00
- BCAB $1.00
- AVG Volume (30 Days)
- CMMB 167.2K
- BCAB 525.8K
- Earning Date
- CMMB 05-08-2025
- BCAB 05-13-2025
- Dividend Yield
- CMMB N/A
- BCAB N/A
- EPS Growth
- CMMB N/A
- BCAB N/A
- EPS
- CMMB N/A
- BCAB N/A
- Revenue
- CMMB N/A
- BCAB $11,000,000.00
- Revenue This Year
- CMMB N/A
- BCAB N/A
- Revenue Next Year
- CMMB N/A
- BCAB N/A
- P/E Ratio
- CMMB N/A
- BCAB N/A
- Revenue Growth
- CMMB N/A
- BCAB N/A
- 52 Week Low
- CMMB $0.58
- BCAB $0.24
- 52 Week High
- CMMB $2.55
- BCAB $3.53
- Technical
- Relative Strength Index (RSI)
- CMMB 50.27
- BCAB 60.29
- Support Level
- CMMB $1.08
- BCAB $0.30
- Resistance Level
- CMMB $1.25
- BCAB $0.34
- Average True Range (ATR)
- CMMB 0.11
- BCAB 0.04
- MACD
- CMMB 0.04
- BCAB 0.01
- Stochastic Oscillator
- CMMB 83.65
- BCAB 92.85
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.